Version history

{
  "session_id": "sess_SDA-2026-04-11-gap-debate-20260410-111106-df334a52",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "support",
  "content": "\n\nI'll execute systematic searches to ground the therapeutic window hypothesis in actual evidence, then provide concrete, testable hypotheses.\n\n[TOOL_CALL]\n{tool => \"pubmed_search\", args => {\n  --query \"GZ SAR402671 venglustat Parkinson disease clinical trial discontinuation safety\"\n  --max_results 25\n}}\n[/TOOL_CALL]\n[TOOL_CALL]\n{tool => \"pubmed_search\", args => {\n  --query \"eliglustat CNS penetration brain substrate reduction GBA Parkinson\"\n  --max_results 25\n}}\n[/TOOL_CALL]\n[TOOL_CALL]\n{tool => \"pubmed_search\", args => {\n  --query \"GCS inhibitor substrate reduction therapy alpha-synuclein mouse model GBA-PD efficacy dose\"\n  --max_max_results 25\n}}\n[/TOOL_CALL]\n[TOOL_CALL]\n{tool => \"pubmed_search\", args => {\n  --query \"Gaucher disease heterozygote glucocerebrosidase GBA mutation Parkinson risk neurotoxicity mechanism\"\n  --max_results 20\n}}\n[/TOOL_CALL]",
  "tokens_used": "216",
  "persona_id": "persona-domain_expert"
}